A Novel Two-Component VLP Technology for the Development of Vaccines Against Respiratory Viruses
Time: 4:15 pm
day: Day One Morning
Details:
- Vaccine technology covering an RSV/hMPV bivalent vaccine as well as a SARS2 candidate which is in Ph1 testing now in Australia
- Advantages of computational protein design to better inform antigen formulation and to achieve higher efficacy rates
